PacBio Q1 FY26 GAAP net loss narrows to $8.3 million; revenue flat at $37.2 million

Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.

PACB

0.00
  • Pacific Biosciences posted Q1 2026 revenue of USD 37.2 million, unchanged year over year, while GAAP net loss narrowed to USD 8.3 million, or USD 0.03 per share.
  • Consumable revenue rose 8.46% to USD 21.8 million, while instrument revenue fell 11.82% to USD 9.7 million.
  • GAAP gross margin swung to 35% from negative 4%, while non-GAAP gross margin slipped 3 percentage points to 37% due to higher computing component costs, temporary first-quarter promotions for Vega, and inventory and warranty-related adjustments and charges.
  • Revio system placements increased to 15 from 12, while Vega system placements edged down to 27 from 28; annualized Revio pull-through per system eased to about USD 229,000 from about USD 236,000.
  • PacBio completed sale of short-read sequencing assets for about USD 48.1 million in net cash proceeds, planned a broad SPRQ-Nx commercial rollout to all Revio customers later this month, and forecast full-year 2026 revenue of USD 165 million to USD 175 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.